Mustang Bio, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 4.70%35.420.9%$1191.39m
JNJJohnson & Johnson 2.07%145.320.7%$1036.46m
BMYBristol-Myers Squibb Co. 1.41%58.241.0%$935.02m
MRKMerck & Co., Inc. 1.93%78.210.7%$802.87m
ABBVAbbVie, Inc. 2.02%98.791.9%$740.36m
LLYEli Lilly & Co. 1.28%165.461.1%$650.06m
AZNAstraZeneca Plc 0.83%54.211.2%$290.91m
RPRXRoyalty Pharma Plc -3.97%45.750.1%$195.68m
NVSNovartis AG 0.25%87.230.2%$143.67m
RGENRepligen Corp. 1.94%128.587.1%$117.58m
GSKGlaxoSmithKline Plc 1.35%40.450.2%$111.37m
NVONovo Nordisk A/S 0.93%66.050.1%$89.30m
RETAReata Pharmaceuticals, Inc. 1.26%156.353.4%$80.43m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.15%74.250.0%$67.66m
SNYSanofi 2.21%51.390.2%$65.15m

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.